Last reviewed · How we verify
insulin regular IV infusion
Insulin regular binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.
Insulin regular binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus (when oral agents insufficient), Acute hyperglycemia and diabetic ketoacidosis.
At a glance
| Generic name | insulin regular IV infusion |
|---|---|
| Sponsor | Rush University Medical Center |
| Drug class | Insulin (short-acting human insulin) |
| Target | Insulin receptor (IR) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Insulin regular is a short-acting human insulin that mimics endogenous insulin secretion. It binds to insulin receptors on muscle, fat, and liver cells, facilitating glucose transport into cells and promoting glycogen synthesis while inhibiting gluconeogenesis. When administered intravenously, it provides rapid glucose control suitable for acute hyperglycemia and perioperative management.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus (when oral agents insufficient)
- Acute hyperglycemia and diabetic ketoacidosis
- Perioperative glycemic control
Common side effects
- Hypoglycemia
- Injection site reactions
- Lipodystrophy
- Weight gain
- Hypokalemia
Key clinical trials
- Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance (PHASE4)
- Glycemic Targets During CPB in Elderly Diabetes (NA)
- Allo HSCT for High Risk Hemoglobinopathies (PHASE2)
- PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM) (PHASE2)
- Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test (PHASE1)
- Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals. (NA)
- Prevention and Treatment of Common Hyperglycemia in Surgery Pilot (PHASE4)
- FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- insulin regular IV infusion CI brief — competitive landscape report
- insulin regular IV infusion updates RSS · CI watch RSS
- Rush University Medical Center portfolio CI